Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability

Cancer Gene Therapy

Volumn 18, Issue 12, 2011, Pages 897-905

  Gu, W ^a   Yeo, E ^a   McMillan, N ^a   Yu, C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cancer stem cells; cervical cancer; HeLa cells; HPV E6 E7; lentiviral vector; RNA interference; self renewal gene; sphere forming cells; TGF

Indexed keywords

CD24 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HERMES ANTIGEN; LEUKEMIA INHIBITORY FACTOR; RAS PROTEIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CANCER STEM CELL; CARCINOGENICITY; CELL GROWTH; CELL ISOLATION; CELL RENEWAL; CERVICAL CANCER STEM LIKE CELL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; UTERINE CERVIX CANCER;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; HELA CELLS; HUMANS; LEUKEMIA INHIBITORY FACTOR; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, VIRAL; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TRANSFORMING GROWTH FACTOR BETA; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 81155130805     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.58     Document Type: Article

References (47)

1. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
2. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 2009; 27: 901-908.
3. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26: 1357-1360. (Pubitemid 46328461)
4. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007; 3: 245-250. (Pubitemid 351492648)
5. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825. (Pubitemid 40559643)
6. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-820. (Pubitemid 39070854)
7. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188. (Pubitemid 36078049)
8. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438. (Pubitemid 34826845)
9. Schomber T, Kalberer CP, Wodnar-Filipowicz A, Skoda RC. Gene silencing by lentivirus-mediated delivery of siRNA in human CD34f cells. Blood 2004; 103: 4511-4513. (Pubitemid 38745977)
10. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R et al. A status report on RNAi therapeutics. Silence 2010; 1: 14.
11. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference-new hope for a highly specific cancer treatment? Cancer Cell 2002; 2: 167-168. (Pubitemid 41043969)
12. Sledz CA, Williams BR. RNA interference in biology and disease. Blood 2005; 106: 787-794. (Pubitemid 41076416)
13. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041-6048.
14. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005; 68: 1311-1319. (Pubitemid 41539987)
15. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13: 1023-1032. (Pubitemid 44564738)
16. Yamato K, Fen J, Kobuchi H, Nasu Y, Yamada T, Nishihara T et al. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 2006; 13: 234-241. (Pubitemid 43255760)
17. Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, Kaufmann M et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004; 6: 786-795. (Pubitemid 40041497)
18. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Research 2005; 7: R220-R228.
19. Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 2004; 11: 748-756. (Pubitemid 39488473)
20. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 2007; 98: 1505-1511. (Pubitemid 47308443)
21. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350. (Pubitemid 37328947)
22. Chang JT, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HF et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers. Cancer Gene Ther 2010; 17: 827-836.
23. Jonson AL, Rogers LM, Ramakrishnan S, Downs Jr LS. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 2008; 111: 356-364.
24. Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J et al. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 2008; 13: 273-281.
25. Tang S, Tao M, McCoy Jr JP, Zheng ZM. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 2006; 25: 2094-2104.
26. Gu W, Cochrane M, Leggatt GR, Payne E, Choyce A, Zhou F et al. Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. Proc Natl Acad Sci USA 2009; 106: 8314-8319.
27. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270. (Pubitemid 36583168)
28. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123. (Pubitemid 350235025)
29. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010; 107: 3722-3727.
30. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
31. Li F. Every single cell clones from cancer cell lines growing tumors in vivo may not invalidate the cancer stem cell concept. Mol Cells 2009; 27: 491-492.
32. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
33. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
34. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I et al. TGF-beta increases glioma-initiating cell selfrenewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-327.
35. Grusch M, Petz M, Metzner T, Ozturk D, Schneller D, Mikulits W. The crosstalk of RAS with the TGF-beta family during carcinoma progression and its implications for targeted cancer therapy. Curr Cancer Drug Targets 2010; 10: 849-857.
36. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 2009; 19: 385-394.
37. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-176.
38. Watabe T, Miyazono K. Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 2009; 19: 103-115.
39. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C et al. Differential expression of transforming growth factors-beta1,-beta2 and-beta3 in human colon carcinoma. Eur J Cancer 2001; 37: 224-233. (Pubitemid 32144700)
40. Charette ST, McCance DJ. The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner. Oncogene 2007; 26: 7386-7390. (Pubitemid 350115975)
41. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res 2006; 66: 5555-5559. (Pubitemid 43927104)
42. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13: 59-67. (Pubitemid 36269181)
43. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009; 417: 411-421.
44. Safina AF, Varga AE, Bianchi A, Zheng Q, Kunnev D, Liang P et al. Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion. Cell Cycle 2009; 8: 284-298.
45. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008; 3: e3077.
46. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281-16286.
47. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284. (Pubitemid 40488633)